Relmada Therapeutics
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2222 Ponce De Leon Blvd Fl 3, Coral Gabl...Phone Number
(786) 629-1376Website
www.relmada.comRevenue
<$5 MillionStock Symbol
RLMDIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Relmada Therapeutics
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.Explore more
Relmada Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
MT
Corporate Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Relmada Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Relmada Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Relmada Therapeutics
Product Launch: Get notified when Relmada Therapeutics launches new products
Click to see if Relmada Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Relmada Therapeutics has new funding data
Check if Relmada Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Relmada Therapeutics is spiking on competitors!
Relmada Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Relmada Therapeutics
Find more new buyers
Compare Similar Companies to Relmada Therapeutics
Compare insights from companies similar to Relmada Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Relmada Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Relmada Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Relmada Therapeutics.
Relmada Therapeutics financials insights
Gather financial insights about Relmada Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$6.9M
2026
Stock/Share Issuance
$160M
Relmada Therapeutics Tech Stack
A closer look at the technologies used by Relmada Therapeutics
See more technologies
Most Recent Scoops
Project
Relmada Therapeutics has outlined a 12-month enrollment timeline for the high-risk, second-line (87 patients), with interim data expected to be presented every three months given the open-label, single-arm design.
Clinical Operations
Project
Relmada Therapeutics has outlined an 18-month enrollment timeline for the intermediate-risk adjuvant (276 patients), a randomized two-arm study versus observation, with full data to be presented only upon trial completion per FDA requirements.
Pharmaceuticals, Clinical Operations
Project
Relmada Therapeutics has reported Phase II, achieving an any-time complete response (CR) rate of 95% and a 12-month CR rate of 76%, including an 80% response rate in patients with bladder cancer unresponsive to BCG. If confirmed in Phase III, these results are expected to represent a significant advance in the treatment of bladder cancer.
Medical Research, Clinical Operations
Project
Relmada Therapeutics has announced that 18-month, including results from a larger patient cohort at the 3, 6, and 12 month timepoints, is expected to be available in early to mid Q4, with a data summary presentation planned before year-end.
Clinical Operations
Project
Clinical Operations
Relmada Therapeutics News & Media
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data for its NDV-01 candidate, which showed a 95% complete response rate in high-risk non-muscle invasive bladder cancer. The company is well-capitalized with $234 […]Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk’s deep expertise in CNS translational science, neuroactive steroid biology, and clinical development will be instrumental in advancing sepranolone,Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Relmada Therapeutics
Sign Up For FreeTo access detailed company insights
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE... Read More
